mRNA Synthesis Raw Materials Market Report Scope & Overview:

The mRNA Synthesis Raw Materials Market was valued at USD 1.85 Billion in 2025 and is expected to reach USD 3.89 Billion by 2035, growing at a CAGR of 7.70% from 2026 to 2035.

The mRNA Synthesis Raw Materials Market comprises critical reagents, enzymes, nucleotides, capping agents, templates, and supporting consumables required for in-vitro transcription-based production of messenger RNA used in vaccines and therapeutics. The growing mRNA vaccine and therapeutic pipeline, higher investment in cell and gene therapy research and development, the increasing need for high-quality synthesis reagents, and the expansion of GMP-compliant manufacturing by biotechnology and pharmaceutical companies continue driving this growth. As developments in the field of mRNA move into the realm of oncology and rare disease treatments, the requirement for specialized and quality raw materials becomes ever greater, thus maintaining supply chain resiliency while expanding the market.

In February 2025, Danaher Corporation announced the completion of the expansion of their Marlborough, Massachusetts facility, which increased capacity for high purity enzymes and nucleotides that are required for mRNA synthesis raw materials in biopharmaceuticals.

Market Size and Forecast

• Market Size in 2026E: USD 1.99 Billion
• Market Size by 2035: USD 3.89 Billion
• CAGR: 7.70% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

To Get more information On mRNA Synthesis Raw Materials Market - Request Free Sample Report

mRNA Synthesis Raw Materials Market Trends

• Government stockpiles and regional manufacturing incentives continue underpinning medium-term demand for pandemic preparedness.
• Expansion into oncology and rare-disease pipelines signals a shift from crisis-driven procurement toward a steady demand cycle.
• Rapid technological gains in capping and delivery reagents continue improving mRNA stability and translation efficiency.
• Strategic collaborations between raw material producers, biotech firms, and contract manufacturers continue bolstering supply chain robustness.
• GMP-grade raw material prioritization continues increasing for clinical and commercial applications as the industry matures.

The United States mRNA Synthesis Raw Materials Market Outlook

The United States mRNA Synthesis Raw Materials Market was valued at USD 0.71 Billion in 2025 and is expected to reach USD 1.49 Billion by 2035, growing at a CAGR of 7.67% from 2026 to 2035.

The USA was the leader of the mRNA synthesis raw materials market globally, registering substantial growth on account of further development of mRNA technologies for vaccines and therapeutics, thereby demanding large volumes of specific raw materials for research and production purposes. In-vitro transcription of mRNA for vaccines and therapeutics required large volumes of nucleotides and other raw materials, which ensured the dominance of the country on the technology market all year round.

Aldevron began operations at its new GMP plasmid DNA facility in Fargo, North Dakota in December 2024, aimed at supplying mRNA vaccine developers with high-quality plasmid DNA templates required for the in-vitro transcription manufacturing process.

mRNA Synthesis Raw Materials Market Segmentation Analysis

• By Type, the nucleotides segment held approximately 38.50% share in mRNA synthesis raw materials market in 2025, while the capping agents segment is the fastest growing.
• By Application, the vaccine production segment held approximately 85.00% share in mRNA synthesis raw materials market in 2025, while the therapeutics production segment is the fastest growing.
• By End User, the biopharmaceutical pharmaceutical companies segment held approximately 50.00% share in mRNA synthesis raw materials market in 2025, while the CDMOs segment is the fastest growing.
• By Raw Material Grade, the GMP-grade segment held approximately 58.00% share in mRNA synthesis raw materials market in 2025, while the research-use-only segment is the fastest growing.

By Type, nucleotides led the mRNA synthesis raw materials market, capping agents grew fastest

In 2025, the nucleotides segment took the lead in terms of types, accounting for nearly 38.50% of overall revenue due to the presence of fundamental components such as adenine, uracil, cytosine, and guanine that form mRNAs. The use of modified nucleotides remains an important factor in stabilizing mRNAs as well as preventing any immune response and the in-vitro transcription of mRNA for mRNA vaccines and therapies still requires huge volumes of raw materials.

The capping agents segment is projected to grow at the fastest CAGR during the forecast period, driven by rising demand for advanced capping technology that improves stability and translation yields for increasingly sophisticated mRNA constructs. As mRNA technology advances into oncology and rare disease applications requiring longer-lasting, more stable mRNA molecules, capping agent innovation continues pushing this type category's growth rate well ahead of the broader type segmentation.

By Application, vaccine production led the mRNA synthesis raw materials market, therapeutics production grew fastest

The vaccine production segment held the largest application share in 2025, at approximately 85.00%, reflecting the sector's continued reliance on mRNA vaccine platforms across both pandemic preparedness and routine immunization programs. That established, large-scale vaccine manufacturing base keeps this application category firmly at the center of overall mRNA synthesis raw materials demand across nearly every major biopharmaceutical market worldwide.

The therapeutics production segment is projected to grow at the fastest CAGR during the forecast period, rapidly gaining ground as oncology and rare disease pipelines increasingly require specialized synthesis inputs and advanced capping technologies for enhanced translation efficiency. Rising clinical trial activity for mRNA-based cancer and genetic disease treatments continues pushing this application category's growth rate ahead of the broader application segmentation.

By End User, biopharmaceutical pharmaceutical companies led the mRNA synthesis raw materials market, CDMOS grew fastest

The biopharmaceutical pharmaceutical companies segment held the largest end-user share in 2025, at approximately 50.00%, anchored by in-house research and manufacturing capability that large biopharmaceutical companies continue maintaining for their mRNA vaccine and therapeutic pipelines. That established in-house manufacturing infrastructure keeps this end-user category firmly at the top of the broader end-user segmentation across nearly every major mRNA program worldwide.

The CDMOs segment is projected to grow at the fastest CAGR during the forecast period, as smaller biotech firms and even larger pharmaceutical companies increasingly rely on contract development and manufacturing organizations to access specialized mRNA synthesis capability without building costly in-house infrastructure. Rising outsourcing of mRNA raw material sourcing and processing continues pushing this end-user category's growth rate ahead of the broader end-user segmentation.

By Raw Material Grade, GMP-grade led the mRNA synthesis raw materials market, research-use-only grew fastest

The GMP-grade segment held the largest raw material grade share in 2025, at approximately 58.00%, reflecting the strict quality and regulatory compliance standards required for clinical and commercial-scale mRNA manufacturing. That regulatory requirement keeps GMP-grade materials firmly at the top of the broader raw material grade segmentation across nearly every major commercial mRNA production program worldwide.

The research-use-only segment is projected to grow at the fastest CAGR during the forecast period, as expanding early-stage development activity across academic institutions and biotech startups continues driving demand for lower-cost research-grade raw materials suited to preclinical and exploratory work. Rising global mRNA research activity continues pushing this raw material grade category's growth rate ahead of the broader raw material grade segmentation.

Regional Analysis

North America mRNA Synthesis Raw Materials Market Insights

North America held the largest share of the global mRNA synthesis raw materials market in 2025, at approximately 38.50%, supported by the region's concentration of leading biotechnology and pharmaceutical companies alongside substantial government investment in pandemic preparedness and biotechnology research. Continued expansion of GMP-compliant manufacturing capacity kept the region firmly ahead of every other region in this market throughout the year.

The U.S. had approximately 85.80% share in terms of regional revenue due to the high density of mRNA raw materials providers and biopharmaceutical producers in this region. The contribution of Canada to regional revenue is smaller but rising consistently due to its increasing biotechnology research environment, which keeps North America ahead of all other regions in this industry.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe mRNA Synthesis Raw Materials Market Insights

Europe held a substantial share of the global mRNA synthesis raw materials market in 2025, supported by strong biopharmaceutical manufacturing and growing biotechnology research investment across the continent. Germany accounted for roughly 27.30% of regional revenue, supported by its concentration of biotechnology companies and advanced GMP-compliant manufacturing infrastructure.

France, the United Kingdom, and Switzerland followed a broadly similar trajectory, as continued mRNA vaccine and therapeutic pipeline expansion extended raw materials demand across the continent's largest biopharmaceutical markets. Continued regulatory support for advanced therapeutics is expected to keep supporting steady European demand through the remainder of the forecast period.

Asia Pacific mRNA Synthesis Raw Materials Market Insights

Asia Pacific was the fastest-growing region in the global mRNA synthesis raw materials market, driven by rising biotechnology investment, expanding domestic vaccine manufacturing capacity, and growing government support for mRNA technology development across the region's largest economies. Rising clinical trial activity continued driving regional demand at a pace considerably faster than more mature Western markets.

China accounted for roughly 36.40% of regional revenue, supported by aggressive domestic biotechnology policy and expanding mRNA vaccine manufacturing capacity. Japan and South Korea contributed significant additional regional demand through their own advanced biopharmaceutical research infrastructure, reinforcing Asia Pacific's position as the clear growth leader in this market.

MEA & Latin America mRNA Synthesis Raw Materials Market Insights

The region of Middle East and Africa showed constant growth in mRNA synthesis raw material acceptance in the year 2025 due to increasing vaccine production processes within the country along with the investments made by the government in biotechnological infrastructure within Gulf countries. The UAE was one of the major contributors to regional revenue accounting for about 26.60%.

Latin America expanded at a comparable pace, led by Brazil at roughly 37.20% of regional revenue, where growing domestic vaccine manufacturing activity continued to support category growth. Mexico and Argentina followed a similar trajectory as regional biotechnology research infrastructure expanded further through the remainder of the forecast period.

Growth Drivers: Expanding mRNA pipeline and GMP manufacturing investment

The growing mRNA vaccine and therapeutic pipeline, combined with higher investment in cell and gene therapy research and development, continues to be the central force behind mRNA synthesis raw materials market growth. The increasing need for high-quality synthesis reagents and the expansion of GMP-compliant manufacturing by biotechnology and pharmaceutical companies continue reinforcing structural demand growth across nearly every major mRNA program worldwide.

Government stockpiles, regional manufacturing incentives, and rapid technological gains in capping and delivery reagents continue underpinning medium-term growth as the sector shifts from crisis-driven procurement toward a steady demand cycle. Expansion into oncology and rare-disease pipelines signals genuinely durable, long-term demand well beyond the market's original pandemic-era origins.

Restraints: Supply chain concentration and specialized manufacturing complexity

The speciality of the raw materials needed for high purity mRNA manufacturing persists in focusing the production capability of only a few reliable manufacturers who can meet the GMP standards. Such a specialization persists in posing a real risk for the supply chain of biopharmaceutical firms relying on these inputs.

The complex bioprocessing infrastructure and stringent quality control required for GMP-grade raw material production continues requiring substantial capital investment that can restrict new supplier entry into the market. That capital intensity continues keeping the most advanced, highest-purity raw material production concentrated among well-capitalized, established life sciences companies.

Opportunities: CDMO capacity expansion and therapeutics pipeline diversification

Growing reliance on contract development and manufacturing organizations for mRNA raw material processing presents substantial opportunity for CDMOs positioned to serve biotech firms and pharmaceutical companies seeking specialized capability without in-house infrastructure investment. CDMOs capable of delivering scalable, GMP-compliant raw material processing stand to capture a growing share of demand as outsourcing trends continue.

Continued diversification of the mRNA therapeutics pipeline beyond vaccines into oncology and rare disease treatment presents a further significant growth avenue, as these applications require specialized, high-quality raw materials distinct from vaccine-focused production. Suppliers capable of delivering therapeutics-grade raw materials stand to capture meaningful new revenue streams as this pipeline diversification continues through 2035.

Recent Developments:

• 2024: Thermo Fisher Scientific entered into a strategic agreement with Moderna in November to supply custom raw materials for the company's next-generation mRNA therapeutics, reinforcing the company's position as a key raw material supplier to leading mRNA developers.
• 2025: Yeasen Biotechnology continued expanding its enzyme and nucleotide manufacturing capacity, strengthening its position serving Chinese and international biopharmaceutical customers requiring high-purity mRNA synthesis raw materials.
• 2026: Aldevron renewed and expanded its licensing agreement with Minaris/Oxgene to provide regulatory-ready lentiviral plasmid systems across research, GMP-Source, and cGMP grades, strengthening supply chain support for cell and gene therapy manufacturing.

mRNA Synthesis Raw Materials Market key players are:

• Danaher Corporation
• Aldevron
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Yeasen Biotechnology (Shanghai) Co., Ltd.
• Merck KGaA
• Agilent Technologies, Inc.
• New England Biolabs, Inc.
• TriLink BioTechnologies, LLC
• Jena Bioscience GmbH
• GenScript Biotech Corporation
• Kaneka Corporation
• Solvias AG
• Repligen Corporation
• Codexis, Inc.
• Creative Biolabs
• Lonza Group AG
• Sartorius AG
• Bio-Rad Laboratories, Inc.
• Promega Corporation

mRNA Synthesis Raw Materials Market Report Scope :